Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Samuel A. Wells(King's College London), Martin Schlumberger(Institut Gustave Roussy), Julie Ann Sosa(Golden Gate University), Robert F. Gagel(The University of Texas MD Anderson Cancer Center), Michael A. Skinner(Imperial College London), Annetta Krebs(The University of Texas MD Anderson Cancer Center), James R. Vasselli(The University of Texas MD Anderson Cancer Center), David G. Pfister(Memorial Sloan Kettering Cancer Center), Jeffrey F. Moley(The University of Texas MD Anderson Cancer Center), Jessica E. Gosnell(The University of Texas MD Anderson Cancer Center)
Cited by 517
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
|Journal of Clinical Oncology|2003|1.4k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863